Concern about adverse reactions to drugs is not new. In 1887 at a meeting in Manchester the British Medical Association set up a small committee to examine the sudden and unexpected deaths which sometimes occurred during chloroform anaesthesia. This was the first collaborative investigation of an adverse reaction of a drug in human subjects. Professor McKendrick, Professor of Physiology in Glasgow, and Dr Coats, pathologist, and Dr Newman, pathological chemist, at the Western Infirmary, Glasgow (1880) reported that chloroform was hazardous in man not only because excessive doses depressed respiration but because small doses had a deleterious effect on the heart and might cause cardiac arrest. This report was contrary to the experience of many who had used chloroform extensively. Its findings were repudiated by Surgeon Major Lawrie, Residency Surgeon at Hyderabad in the Deccan, with such heat that it is surprising that the now yellowing pages of the Lancet of 1889 and 1890 are not a little charred. Major Lawrie appointed two Hyderabad Chloroform Commissions, on both of which he sat as President. Following the extensive administration of chloroform to dogs that Commission in its final report stated, in the words of a contemporary Anglo-Indian, that chloroform given in doses which did not cause respiratory depression was 'as safe as whisky and water' (Lawrie, Brunton, Bomford, and Hakin, 1890) . But the report received little attention in Britain for here it was already indisputable that in human beings sudden death did sometimes occur in the early stages of chloroform anaesthesia.
This ancient controversy is worth recalling. It not only showed for the first time the enormous emotion that mayAbe aroused in doctors when a drug which they value is found to cause serious adverse reactions, but it also demonstrated, although the (Taussig, 1962 Council (1963) not only gave advice about the way in which a system of notification of adverse reactions by doctors using drugs should be established but stated: 'Early recognition alone is not always enough. The purpose of determining the toxic effects (of a drug) in man will usually be to obtain intelligent restriction of its further use. To make such a decision possible it is necessary not only to recognize the toxic effect but also to estimate its incidence and to compare that with the danger of the diseases for which the drug is being used.'
These wise words bear repetition for hasty and unnecessary decisions to ban the use of a drug have been a feature of recent years and are often the result of undue, unbalanced, and sometimes premature publicity by the press which lead to overreaction of the public or politicians. It is, however, now widely recognized that there is a need not only to identify the adverse reactions to a drug but to determine their incidence in relation to the use of the drug. The data available to answer such questions have come from sources each of which has had its limitations. (Meyler, 1957; Meyler and Herxheimer, 1968 dyscrasias suspected as due to drugs were received. The number of reports received was small: this was due to poor publicity, the novelty of the scheme, and the dauntingly detailed form which had to be filled in. There was also anxiety, which persists in the United States, that by reporting an illness as due to a drug he has prescribed, a physician might expose himself to a charge of negligence by his patient. The establishment of this registry by Dr Wintrobe marks the beginning of systemic monitoring of adverse reactions to drugs (Erslev and Wintrobe, 1962 (Inman and Vessey, 1968) . It is known, too, that many deaths of asthmatic patients using isoprenaline aerosols were never reported, but this was because the relationship between these aerosols and sudden death was unsuspected (Inman and Adelstein, 1969 
Intensive Monitoring
The seriousness of an adverse reaction depends not only on its nature but also on its frequency in relation to the use of a drug. In the US Army Custer (1946) determined the incidence of aplastic anaemia due to the antimalarial drug mepacrine with a precision which will seldom be equalled. He showed that the incidence was 2-84 per 100 000 men taking mepacrine compared with 0-1 per 100 000 men not taking mepacrine. In spite of this low incidence, Custer' (Wade, 1970) . All the data are recorded on computer tape to allow payments to be made to pharmacists and we have been able to follow the change of prescribing of individual drugs over time. Figure 1 shows the changes in the prescribing of hypnotic drugs between 1966 and 1970 (Wade and Hood, 1972a (Wade and Hood, 1972b ). It has also been possible to study the geography of drug use. One of our first studies was of the use of insulin and oral hypoglycaemic drugs (Wade, Hadden, and Hood, 1972) . The prescribing of insulin was remarkably evenly distributed throughout the province. But there were great variations in the prescribing of oral hypoglycaemic drugs (fig 3) . At the time of the survey (1966) the drugs being mainly used were tolbutamide and chlorpropamide. A detailed survey was made of the use of these drugs in Londonderry and Newry, low-and high-use areas respectively (table VII). It was found that in each city almost exactly the same proportion of persons were receiving oral hypoglycaemic drugs. The difference in overall use was due to the low daily doses prescribed for each patient in Londonderry and the high doses in Newry. I suspect that the main reason for this difference was that in Londonderry the diabetic clinic had a dietician who gave advice and detailed supervision of patients. In Newry there was no dietician. These observations may be important in relation to the anxiety raised by the University Diabetic Group Project (1970) Recently it has been possible to carry out a study of the prescribing of the oral hypoglycaemic drugs in Northern Ireland, Norway, and Sweden (Crooks, Elmes, Friebel, Halse et al, 1974) . The analysis is not yet complete but it is clear that the differences in prescribing found within Northern Ireland are very much smaller than the differences which exist between these three countries (fig 4) . It seems to me that if large differences in the prescribing of drugs are occurring it may be possible not only to learn more about the incidence of adverse reactions to the drug but also to assess what value its use is, by comparing the morbidity, span of life, and mortality of communities in which the drug is used with those where it is not used. It has been particularly interesting to find that in one area of Sweden, the county of Jamtland, it is possible not only to 
